
Unum’s Antibody-Directed T Cells: Differentiated from CAR T-Cell and T Cell Receptor Reprogramming
Unum Therapeutics is a new immunotherapy biotechnology company in which Fidelity Biosciences, Atlas Ventures and Sanofi invested $12 MM in a Series A (first venture round) of investment.